

biotech companies tackling today’s biggest challenges.
The Spotlight: A Celebration of MBC BioLabs Founders
MBC BioLabs and Kilroy invite you to a reception celebrating the people who make this industry move: the scientists who took the leap, the founders turning bold ideas into impactful companies, and the investors and partners who back them early. Join us for an evening a few blocks from the conference with room to breathe, talk, and get to know the kind people in our ecosystem.
The reception runs all evening. From the moment doors open, you’ll find a full bar with specialty cocktails, elevated food stations, a photographer and photo booth. Come when you can, stay as long as you like.
Agenda:
4:00 PM – Doors open & Networking
4:30 – 5:00 PM – Backing Early Panel. Hear from investors who back MBC startups. We're bringing together funds that support companies as they take their discoveries from 0 to 1. This is a conversation about where the best early-stage science is coming from and how to recognize it.
5:00 – 5:15 PM – Raise a glass with us. We have something to announce, and we'd love for you to be in the room when we do.
5:15 – 7:30 PM – Meet the founders. Startups from the MBC BioLabs community will be sharing what they’re building in three rounds of 60-second lightning talks, each followed by time at their tables to talk one on one. Every round features a mix of companies across Oncology, Neuro, Immunology, Age-related Diseases, Rare Disease & Women’s Health, and Platforms, Tools & Devices, so whenever you arrive, there’s someone you’ll want to meet. If you’re an investor or pharma partner looking for what’s next, this is where to meet the emerging technology of tomorrow.
Round 1: 5:15 – 6:00 PM
Round 2: 6:00 – 6:45 PM
Round 3: 6:45 – 7:30 PM
7:30 – 8:00 PM – Networking. Whether you're a founder, scientist, investor, or longtime friend of MBC, come enjoy drinks, food, and good company.
Space is limited; register early to save your spot.
Hosted in collaboration with Kilroy
biotech companies tackling today’s biggest challenges.